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Rubidium-82 has a long story, starting in 1954. After preclinical studies in dogs showing
that myocardial uptake of this radionuclide was directly proportional to myocardial blood
flow (MBF), clinical studies were performed in the 80s leading to an approval in the USA
in 1989. From that time, thousands of patients have been tested and their results have
been reported in three meta-analyses. Pooled patient-based sensitivity and specificity
were, respectively, 0.91 and 0.90. By comparison with 99mTc-SPECT, 82Rb PET had a
much better diagnostic accuracy, especially in obese patients with body mass index
30 kg/m2 (85 versus 67% with SPECT) and in women with large breasts. A great
advantage of 82Rb PET is its capacity to accurately quantify MBF. Quite importantly, it has
been recently shown that coronary flow reserve is associated with adverse cardiovascular
events independently of luminal angiographic severity. Moreover, coronary flow reserve
is a functional parameter particularly useful in the estimate of microvascular dysfunction,
such as in diabetes mellitus. Due to the very short half-life of rubidium-82, the effective
dose calculated for a rest/stress test is roughly equivalent to the annual natural exposure
and even less when stress-only is performed with a low activity compatible with a good
image quality with the last generation 3D PET scanners. There is still some debate on the
relative advantages of 82Rb PET with regard to 99mTc-SPECT. For the last 10 years, great
technological advances substantially improved performances of SPECT with its accuracy
getting closer to this of 82Rb/PET. Currently, the main advantages of PET are its capacity
to accurately quantify MBF and to deliver a low radiation exposure.
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Introduction
The story of medical use of rubidium goes back in 1954 when Love et al. showed that the biological
behavior of rubidiumwas comparable to the one of potassium and that its myocardial muscle uptake
was proportional to blood flow in coronary arteries (1). Following this paper, several preclinical
studies have been performed mainly in dogs and using different radionuclides of rubidium until the
early 80s when the first injection in humans took place (2). During the 80s, a few clinical studies,
including hundreds of patients, demonstrated the good diagnostic accuracy of 82Rb/PET, which
was higher than the one obtained with 99mTc/SPECT (3, 4). Subsequently, a generator 82Sr/82Rb
(CardioGen-82®) was approved in 1989 and delivered in the USA by Bracco Diagnostics, Inc., for
clinical use.
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At that time, the number of PET cameras, their technological
performances, and the production capacities of strontium-82were
limited, explaining a slow progression of this technology in the
USA. However, despite this limitation, thousands of patients were
tested with PET using rubidium-82 allowing three meta-analyses
to be performed.
During the last 10 years, with the increased number of PET/CT
systems and the higher strontium-82 production capabilities, the
number of patients injected with rubidium-82 in theUSA dramat-
ically grew even if it still represents a small percentage by com-
parison with the use of 99mTc-sestamibi and 99mTc-tetrofosmin.
Moreover, for the last 10 years, great technological advances have
been introduced, including semiconductor detector SPECT scan-
ners, novel collimator design, and novel iterative reconstruc-
tion methods allowing to substantially improve count sensitivity
and image resolution. Consequently, the diagnostic accuracy of
99mTc/SPECTgot closer to this of 82Rb/PET, opening a large debate
on the advantages of one technique with regard to the other.
The latest clinical developments zeroed in on the high prognos-
tic value of quantification using PET and allowing to accurately
measure myocardial blood flow (MBF) and coronary reserve.
Even if there are no real technical limitations to such measure-
ments with SPECT it will take some years before their poten-
tial clinical validation (5). Finally, the level of radiation dose is
an important parameter to be taken into consideration due to
the high number of patients to be tested and the repetition of
imaging in the same patients. The aforementioned technological
advances allowed to significantly reduce radiation doses with both
99mTc/SPECT and 82Rb/PET even if the latter delivers the smallest
dose (6).
Preclinical Studies
Beta- and gamma-emitting rubidium-86 was first used because
its long 18.7 days half-life enabled to perform long-lasting kinetic
studies. In 1959, Love et al. showed, in 19 dogs, that myocardial
uptake of this radionuclide was directly proportional to MBF (7).
These results were confirmed 2 years later in 26 dogs by Levy
et al. (8).
More than a decade later, Nishiyama et al. compared opti-
mal settings of scintillation camera with 201Tl (T1/2:73.1 h, γ:
167 keV), 43K (T1/2: 22.2h, γ: 373 keV), 129Cs (T1/2: 32.06h,
γ:372 keV), and 81Rb, a positron-emitting radioisotopewith a half-
life of 4.6 h (9). Thallium-201 was considered as the best suited
with the available equipment at that time and cesium-129was next
best. High-energy photons from 81Rb largely made it impossible
to obtain an interpretable image without the addition of more
shielding.
In 1979, Yano et al. compared several ion-exchange columns
to be used in an automated 82Sr/82Rb generator for testing in
man (10).
Finally, in 1982, Selwyn et al. examined the relation between
myocardial perfusion and rubidium-82 uptake during acute
ischemia in six dogs after coronary stenosis and in five volun-
teers and five patients with coronary artery disease. Myocardial
tomograms, recorded at rest and after exercise in the volun-
teers showed homogeneous uptake in reproducible and repeatable
scans. An absolute mean decrease of 36 14% in regional
myocardial uptake was found after exercise in the patients with
coronary artery disease (2).
Clinical Studies
Meta-Analyses of PET Studies
Since the approval by FDA in the USA in 1989, a vast amount
of clinical studies have been performed, including thousands of
patients. Results have been analyzed in three meta-analyses pub-
lished in 2008 and 2012 (Table 1). Pooled patient-based sensitivity
and specificity were, respectively, 0.91 and 0.90. These excellent
results should be tempered by some limitations and biases inher-
ent to meta-analyses. There was heterogeneity between studies in
scanning protocols and prevalence stenosis with invasive coro-
narography. Moreover, baseline characteristics, such as gender
or disease prevalence, were different between patient populations
resulting in a cautious interpretation.
For a long time, PET studies have been performed with
two-dimensional cameras needing to inject a relatively high
activity of rubidium-82 (40mCi for stress-only) and resulting
in non-negligible radiation exposure. The accuracy, outcomes,
and cost-effectiveness of 3D PET technology using a low activ-
ity of 20mCi were recently evaluated in seven centers (14).
Through an effective standardization and quality assurance pro-
gram, the image interpretation was highly repeatable in involved
centers.
Meta-Analyses of SPECT Studies
A much larger number of 227 studies using 99mTc/SPECT and
including more than 14,500 patients have been considered in 7
meta-analyses published between 1998 and 2012 (Table 2). Pooled
patient-based sensitivity and specificity were, respectively, 0.88
and 0.67. The same limitations as with PET studies were applied
to SPECT studies.
Comparison Between PET and SPECT
Myocardial perfusion imaging is a real challenge in overweight
or obese patients and in women with large breasts due to atten-
uation artifacts, resulting in decreased specificity using 99mTc
SPECT. PET imaging has improved specificity owing to better
spatial resolution, coincidence detection, and accurate attenuation
correction.
Bateman et al. compared 99mTc SPECT in 112 patientswith 82Rb
PET in 112 patients (20). They showed a much better diagnostic
accuracy using PET, in obese patients with bodymass index (BMI)
TABLE 1 | Results of meta-analyses with 82Rb PET.
Number of
studies/patients
Patient-based
sensitivity
Patient-based
specificity
Reference
11/1175 0.93 (0.85–0.96) 0.90 (0.75–1.00) (11)
11/NSa 0.84 (0.81–0.87) 0.81 (0.74–0.87) (12)
6/843 0.91 (0.86–0.96) 0.93 (0.60–1.00) (13)
28/2018 0.91 0.90
NS, not specified.
aPooled results.
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TABLE 2 | Results of meta-analyses with 99mTc SPECT.
Number of
studies/patients
Patient-based
sensitivity
Patient-based
specificity
Reference
20/3474 0.90 (0.89–0.90) 0.77 (0.72–0.83) (15)
27/3237 0.87a 0.64a (16)
44/2837 0.89 (0.82–0.90) 0.75 (0.65–0.75) (17)
10/651 0.88a 0.67a (18)
13/2922 0.81a 0.65a (19)
105/NS 0.88 (0.88–0.89) 0.61 (0.59–0.62) (12)
8/1410 0.85 (0.72–0.97) 0.82 (0.76–0.92) (13)
227/14531 0.88 (0.81–0.90) 0.67 (0.61–0.82)
NS, not specified.
aPooled results.
30 kg/m2 (85 versus 67% with SPECT). However, it should be
noted that SPECT was performed at that time without attenua-
tion correction. With the introduction of iterative reconstruction,
SPECT is now performed with attenuation correction, which may
correct some artifacts and improve diagnostic accuracy in the
obese population but with a decrease of sensitivity. A recent study
reported on the value of 82RbPET in 2687 obese patients with BMI
30 kg/m2 by comparison with 2047 overweight patients (BMI:
25.0–30.0 kg/m2) and 1303 normal patients (BMI: <25.0 kg/m2).
Interestingly, the results showed the same prognostic value irre-
spective of BMI (21).
In the future, 82Rb PET should be compared to contempo-
rary 99mTc SPECT using the last technological advances in the
same overweight or obese patients to confirm or not the higher
prognostic value of PET to SPECT.
As aforementioned, a large number of clinical studies have
been performed using PET and SPECT in different populations
of patients allowing to group the results in meta-analyses with the
possibility of biases in interpretation of these results.
The most informative comparison between PET and SPECT
should be in the same population of patients injected with both
radiopharmaceuticals. Such comparisons have been made a long
time ago at the time of approval of rubidium-82 in the USA
in three studies, including a total of 433 patients (22–24). In
fact, these studies used thallium-201 for SPECT, which has been
replaced by technetium-99m. Quite recently, a comparison of
both modalities has been performed in a small cohort of 27
patients using the most recent hybrid imaging technology, which
included CT-based attenuation correction for SPECT and PET
(25). 82Rb/PET imaging was performed as a second-line test when
previous gated rest/stress 99mTc/SPECT with or without atten-
uation correction was non-conclusive. In this clinical situation,
there were much fewer non-conclusive results with PET than with
SPECT. Image quality and interpretive confidence were higher
with PET than with SPECT even when SPECT was performed
with attenuation correction.
Dosimetric Studies
Radiation dosimetry of rubidium-82 has been recently estimated
in 10 healthy volunteers using the OLINDA/EXM 1.0 dosimetry
software (26). Using different methodological approach, the esti-
mates were discrepant with the results previously reported. The
highest absorbed dose was delivered to the kidneys but remaining
at a quite acceptable level of 1.3 cGy for 2220MBq (60mCi) of
injected activity. The effective dose calculated for a rest/stress test
with an injected activity of 2MBq 1480MBq (2mCi 40mCi)
was 3.7mSv that is roughly equivalent to the annual natural
exposure.
In 2015, Dorbala et al. reported on the way to reduce radiation
dose with myocardial SPECT and PET imaging (6). Consider-
ing the use of last generation of 3D PET scanners and software
allowing to inject half activity of rubidium-82 (2MBq 740MBq
or 2mCi 20mCi) for a preserved image quality, the calculated
effective dose was 1.26mSv for rest or stress. In the clinical situa-
tion of stress-only 3D PET with MBF estimate, the radiation dose
would be at an acceptable level of around 1mSv. This is half of
the radiation dose with 99mTc-sestamibi or tetrofosmin using last
generation of scanners.
Quantification Studies
The clinical use of quantitative MBF assessment with 82Rb/PET
started at the end of the previous decade in the USA. In 2009,
El Fakhri et al. demonstrated, in 22 subjects including patients
with known coronary artery disease or healthy volunteers, that the
measurement of absolute quantitation ofMBF was feasible, repro-
ducible, and accurate (27). Two years later, Ziadi et al. prospec-
tively evaluated the prognostic value of coronary flow reserve
using 82Rb/PET in 704 patients and compared the results with
semi-quantitative assessment using summed stress scores (28).
They showed that quantitative myocardial flow reserve (MFR)
was a good predictor of adverse cardiac events independent of the
summed stress scores. The same added prognostic value of blood
flow quantitation was confirmed 2 years later by Farhad et al. in
351 patients (29).
Several software packages are available for quantification of
MBF. A study (RUBY-10) compared them in 48 patients from 10
centers and showed that, using the most common kinetic model,
they may be used interchangeably (30).
The value of quantification of absolute MBF using rubidium-
82 has been studied in 140 patients after heart transplant and for
whom the prognosis depends on allograft vasculopathy (31). It
was clearly shown that mean MFR was a significant predictor of
future adverse events.
The great interest of blood flow quantification has been doc-
umented in diabetes mellitus (32). Among diabetic patients
without coronary artery disease, those with impaired coronary
reserve had cardiac event rates comparable to those with prior
coronary artery disease, whereas those with preserved coronary
reserve had cardiac event rates comparable to those of non-
diabetics. Moreover, it has been recently shown that “global
coronary flow reserve is associated with adverse cardiovascu-
lar events independently of luminal angiographic severity and
modifies the effect of early revascularization” (33). The angio-
graphic severity was evaluated using the coronary artery disease
prognostic index. This important result documents the com-
plementary but distinct association of functional and anatomic
coronary abnormalities. A significant interaction was shown
between coronary flow reserve and revascularization strategy,
which could have large implications in the future for therapeutic
strategy.
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One other cardiac PET perfusion tracer, 13N-ammonia, has
been approved in the USA and is being clinically used at a rela-
tively modest level. Its positron range is favorable resulting in a
good image resolution and the myocardial extraction fraction is
also favorable but its short physical half-life of 9.96min requires
an onsite cyclotron, which is a great limitation for a routine clinical
use. Another PET radiotracer, 18F-flurpiridaz is currently under-
going a clinical phase III evaluation and is quite promising after
its potential approval. It could then be a real competitor to 82Rb.
A recent excellent review described in depth the characteristics of
all PET perfusion radiotracers (34).
Advantages
Daily Availability of Rubidium-82 in Nuclear
Cardiology Departments
Like with all generators, rubidium-82 is daily available in a depart-
ment of nuclear medicine after elution of the column loaded with
strontium-82 (Table 3). Such elution can be repeated every 10min
making possible to inject up to 10–15 patients per day depending
on the availability of a dedicated cardiac PET/CT and of patient
recruitment rate. A 82Sr/82Rb generator can currently be used for
28–42 days according to the loaded strontium-82 activity. It can be
expected that this use will be extended to 60 days in a near future
allowing to increase the number of tested patients with the same
generator and consequently to decrease the cost of rubidium-82
examination for each patient.
Easy Interpretation of Images due to High Count
Density
The count density and the uniformity of distribution of rubidium-
82 in the myocardium are higher with PET than with SPECT
using technetium-99m, even using the last technological advances
of both techniques (25). Consequently, the interpretative confi-
dence and interreader agreement are higher with PET leading to a
higher accuracy. PET cameras do not need the use of collimators,
resulting in higher sensitivity and spatial resolution (35).
Measurement of Myocardial Blood Flow and
Coronary Reserve
Interpretation of SPECT and PET images is visual or semi-
quantitative and based on relative uptake. Myocardial areas with
the highest uptake are supposed to be supplied by non-obstructive
coronary arteries while those with decreased uptake during stress
are considered as being supplied by obstructive arteries. A stenosis
with a luminal diameter around 50% may be undetected by this
visual interpretation. Moreover, patients with subclinical coro-
nary ischemia or microvascular diffuse disease may present only
TABLE 3 |Advantages and disadvantages of the use of 82Rb PETmyocardial
imaging.
Advantages Disadvantages
Quantification++ Cost++
Good interpretative confidence Lack of dedicated cardiac PET cameras
Favorable dosimetry Limited capacity of strontium production
Good diagnostic accuracy
a mild heterogeneous or even homogeneous myocardial uptake.
Finally, in the situation of three-vessel coronary disease, a reduc-
tion ofmyocardial uptakemay be balanced in all coronary arteries,
resulting in a homogeneous left ventricle myocardium at stress
(Figure 1).
The measurements of absolute MBF in milliliter per gram per
minute and MFR, which is the maximum increase in blood flow
above the normal resting volume, allows to complete the field of
application of conventional perfusion imaging by identifying sub-
clinical coronary ischemia and characterizing extent and severity
inmulti-vessel disease.Moreover, it has been clearly shown during
the last years that the measurement of hyperemic MBF and MFR
using PET/CT may predict, better than other parameters, the
occurrence of hard cardiac events.
Today, there is no doubt that absolute myocardial perfusion
quantification has been fully validated using PET/CT with 82Rb
or 13N. There is a great debate about the same possibility using
99mTc/SPECT. In a quite recent editorial, Garcia considered the
current situation taking into account the most recent technolog-
ical advances in instrumentation and quantification software (5).
New heart-centered SPECT systems have a high count sensitivity
and iterative reconstruction enables an efficient correction of
attenuation, scatter, and resolution changes with depth. In 2013,
Ben-Haim et al. (36) showed the feasibility of measuringMBF and
MFR with SPECT. Today, it can be stated that there is no real
limitation to the quantification of MBF and MBF reserve with
SPECT. The first results on clinical efficacy using conventional
SPECT/CT systems have been reported (37) but these preliminary
results should be confirmed in large studies and it will take some
years before full validation for clinical use. Today, there is no doubt
that only PET technology allows tomeasure rapidly and accurately
the MBF.
Low Radiation Exposure for Patients
Given the high and still increasing number of patients who have
myocardial perfusion imaging all over the world each year, the
radiation exposure for patients and medical staff is a real concern
and should be reduced at the lowest level compatible with a good
image quality.
Effective radiation dose is directly related to the physical half-
life of the radiopharmaceutical, its biodistribution and injected
activity. In this respect, the very short half-life of 82Rb of 1.26min
in comparison of 6 h of 99mTc is quite favorable for a low radia-
tion dose, especially if new technologies enable to substantially
decrease injected activity. For a long time, using 2D imaging
mode, injected activity of rubidium-82 for rest and stress was
1480MBq (40mCi), resulting in an estimated dose of 2.5 and
5mSv, respectively (6). Shifting from 2D to 3D imaging mode
allowed to inject half activity (740MBq or 20mCi) for the same
image quality and then to reduce the dose to 1.3mSv for stress
or rest and even to <1mSv using new estimates of rubidium-82
dose (26). Such a dose is acceptable when compared to an average
natural annual radiation dose of about 3mSv. Stress-only PET
3D imaging, allowing to measure hyperemic MBF with <1mSv,
would be the preferred strategy for risk stratification if this mea-
surement is clinically validated with regard to the measurement
of myocardial blood reserve, which needs both stress and rest
tests.
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FIGURE 1 | A 56-year-old woman with a history of obesity (BMI: 31.2 cm/kg2), hypertension, hyperlipemia, and type 2 diabetes complicated of
retinopathy and renal failure. The patient was referred to the Nuclear Medicine department for detection of coronary artery disease and underwent both
Tc-99m-sestamibi SPECT (D-SPECT, Spectrum Dynamics, Haifa) and rubidium-82 PET/CT (Discovery 690 VCT, GEMS, Buc, France) as part of a clinical trial.
SPECT (93% of the predicted maximal heart rate, no symptoms, EKG positive) was normal with a homogeneous uptake of the tracer both at stress and at rest (A).
82Rb PET performed after Dipyridamole infusion showed a mild decrease of the tracer uptake in the lateral wall (arrow), completely reversible at rest, raising the
suspicion of ischemia in the territory of the circumflex artery (B). This hypothesis was then confirmed by quantitative data derived from myocardial blood flow
measurement with a coronary steal phenomenon in the same territory [coronary flow reserve (CFR) <1; (C)]. In addition, the CFR was markedly decreased (<1.5) in
the territory of both the left descending artery and the right coronary artery, suggesting the presence of significant stenosis of these two coronary arteries. The
coronary angiography confirmed the diagnosis of three-vessel disease and the patient underwent surgical revascularization. This case report underlines the greatest
sensitivity of 82Rb PET over SPECT in the setting of balanced ischemia, in relation with the ability to perform absolute quantification of myocardial blood flow.
By comparison, effective radiation doses are higher with 99mTc-
based radiopharmaceuticals partially owing to the longer half-
life of this radionuclide with regard to rubidium-82. Using the
most recent advances in cardiac SPECT technology allowing to
inject half activity for the same image quality [148–444MBq
(4–12mCi)], the estimated doses are 2.3 and 8mSv for rest/stress
with 99mTc sestamibi and 2.0 and 6.1mSv with 99mTc-tetrofosmin
(6). Stress-only SPECT 3D imaging would deliver twice higher
effective dose than with stress-only PET 3D imaging even if such
dose remains moderate.
A recent study reported on projected population cancer risks
in the USA using myocardial perfusion scintigraphy (38). The
authors considered estimated effective doses ranging from 9mSv
for stress-only technetium-99m to 35mSv for a rest/stress dual-
isotope study associating thallium-201 and technetium-99m and
using conventional SPECT equipment. For rubidium-82 PET
imaging, they considered an estimated effective dose of 15mSv
for a rest/stress test using an injected activity of 1480–2250MBq
and a 2D PET camera. Cancer risk projection models were based
on the National Research Council Biological Effects of Ionizing
Radiation VII report assuming a linear relationship with radiation
exposure. In these conditions and considering the 9.1million tests
performed each year in the USA, the number of additional future
cancers would be about 7400. This number should be viewed with
great caution because, from the time of Berrington’s publication,
estimated effective doses have been substantially decreased with
the use of most advanced instrumentation allowing to dramati-
cally decrease injected activities.
Considering the lower injected activity, which is now possible
with 3D SPECT and PET cameras, which results in low effective
doses, the number of additional and supposed cancers should
be significantly lowered. Finally, the risk/benefit ratio should be
taken into consideration for each individual patient before per-
forming amyocardial perfusion test and the lowest activity should
be injected compatible with a good image quality leading to an
accurate diagnosis.
Limitations
Cost
Currently, the cost for one test with rubidium-82 is higher than
with a 99mTc-labeled radiopharmaceutical even in the favorable
situation of a nuclear cardiology center with a high recruitment
rate (Table 3). In the USA, sestamibi-99mTc is currently reim-
bursed at about $70 per dose, usually using 2 doses. However, in
the hospital setting, the entire procedure including the drug is paid
at $1139. Rubidium-82 is reimbursed at approximately $250 per
dose. In the hospital setting, the entire procedure is reimbursed
$1286.
This relative low cost of technetium-99m is partly due to the fact
that Mo-99/Tc-99m is not paid at full cost which explains some of
the problems encountered nowadays with aging reactors and the
difficulties to build new ones. Consequently, the use of rubidium-
82 should be, at least at short term, limited to patients who are
unable to complete exercise stress test, who are obese or who had
a previous equivocal and non-conclusive SPECT test. Moreover,
Frontiers in Medicine | www.frontiersin.org September 2015 | Volume 2 | Article 655
Chatal et al. Rubidium-82 for myocardial perfusion
rubidium-82 should be used, despite its cost, when MBF and
coronary flow reserve quantitation are required, for example, in
patients with multi-vessel coronary disease.
Some new high-energy cyclotrons will be installed shortly and
will enable to extend strontium-82 availability, and then provide
generators in a cost effective model.
Limited Number and Availability of PET 3D
Systems
To be as cost-effective as possible with a 82Sr/82Rb generator, it
is necessary to test a high number of patients before its expira-
tion date (presently 28–42 days) but this situation needs to have
available a dedicated cardiac PET/CT camera. In Europe, where
a 82Sr/82Rb generator has not been approved yet, there is no
such dedicated PET/CT cameras and the conventional PET/CT
cameras are mainly used in oncology with fluorodeoxyglucose
(FDG). A minimum of 8–10 patients are tested each day with
this radiopharmaceutical and up to amaximum of 15–20 patients.
Consequently, a quite limited number of patients could be injected
with rubidium-82 per day making each test relatively expensive.
This situation reinforces the fact that, at the beginning, Rb-82 will
be probably limited to selective cases (see Cost). It will take prob-
ably a few years before some dedicated cardiac PET/CT cameras
are available in large cardiology centers with a recruitment rate
warranting such equipment.
Perspectives
Strontium-82, which is the parent nucleus of rubidium-82, is
produced using proton beam interacting on a target contain-
ing stable rubidium. To be economically viable, an accelerator
with proton beam of energy higher than 70MeV and intensity
>100μA must be used. There are only few places in the world
where such accelerators are available: BrookavenNational Labora-
tory (BNL-USA), Los Alamos National Laboratory (LANL-USA),
iThemba labs (South Africa), INR (Russia), Triumf (Canada),
and Arronax (France). These accelerators are not dedicated facil-
ities and only part of the beam time is devoted to this produc-
tion. Recently, based on the success of the first prototype of a
70MeV machine built by a commercial cyclotron provider and
installed in Nantes (France), several private companies are con-
sidering the use of such commercial cyclotron for strontium-82
production. Zevacor (USA) is one of them and CDNM (Rus-
sia) is the other one. In parallel, a 70MeV cyclotron is being
installed at Legnaro (Italy) for research purpose but one of the
two available beam lines may be used for radionuclide produc-
tion. This indicates that the availability of strontium-82 in the
future will be higher allowing to secure the supply chain and
enlarge the use of this radionuclide to other countries (at the
moment only north America is using it routinely), especially in
Europe.
From a technological point of view, another advance will
enlarge strontium-82 production, which is the use of rubidium
metal target instead of the rubidium chloride target. With such
change, higher yields can be obtained at the price of a more
technical radiochemical process.
Finally, several designs of strontium-82/rubidium-82 genera-
tors are being studied andmay reach themarket in the future. This
will allow to get generators with extended lifetime (up to 60 days)
or lower activity which will better fit the need of users.
Conclusion
There is no doubt that the advantages of 82Rb/PET myocardial
imaging have been clearly documented since its routine clinical
use after approval in the USA nearly 30 years ago. For a long
time, its accuracy was significantly better than that obtained with
the SPECT/99mTc technology particularly in obese or overweight
patients and women with large breasts due to attenuation correc-
tion artifacts. With the most recent hybrid SPECT imaging tech-
nology, the situation changed, leading to an improved specificity
of 99mTc/SPECT. Currently, the main advantage of 82Rb/PET is its
capacity to accurately measure the MBF and flow reserve. Even if
such measurement is technologically feasible with 99mTc/SPECT,
it will take some years before potential validation. Finally, given
the very short physical half-life of rubidium-82, the radiation
exposure rate with this radionuclide is significantly lower than
with technetium-99m. Using 3D hybrid PET system, it is possible
to inject low activities of rubidium-82 while maintaining a good
image quality. The radiation exposure rate is then acceptable and
inferior to natural exposure.
It can be anticipated that in the future 82Rb/PET and
99mTc/SPECT will continue to be used according availability of
hybrid cameras and radionuclides.
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